1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

US Sickle Cell Gene Therapy Contracting Demo Attracting Interest From States

 
• By Laura Helbling

The US Medicaid agency says states representing more than 80% of sickle cell patients are interested in a centralized contracting program, but House Republicans want legislation, not administrative interventions, to shape value-based payment for curative therapies.

sickle cell disease
The CMMI centralized contracting program is only focusing on sickle cell disease for now, Fowler said. • Source: Shutterstock

A US Medicaid program to test centralized contracting for sickle cell disease gene therapies has attracted widespread interest from state payors.

Key Takeaways

  • States are interested in a CMS program on centralized contracting for gene therapies treating sickle cell disease.

The US Center for Medicare and Medicaid Innovation has received letters of intent from “a majority of states that represent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers

Medicare Part D LIS Access Threatened By House Budget Bill’s Medicaid Obstacles

 
• By Cathy Kelly

An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.

Pharma’s Protests Fall Flat As UK Locks In High Rebate Rates

 
• By Neena Brizmohun

Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.